
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Adaptimmune Therapeutics Plc (ADAP)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: ADAP (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -13.45% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 158.65M USD | Price to earnings Ratio - | 1Y Target Price 2.27 |
Price to earnings Ratio - | 1Y Target Price 2.27 | ||
Volume (30-day avg) 1524917 | Beta 2.25 | 52 Weeks Range 0.53 - 2.05 | Updated Date 02/9/2025 |
52 Weeks Range 0.53 - 2.05 | Updated Date 02/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -51.25% | Operating Margin (TTM) 53.58% |
Management Effectiveness
Return on Assets (TTM) -15.84% | Return on Equity (TTM) -65.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 47052588 | Price to Sales(TTM) 1.12 |
Enterprise Value 47052588 | Price to Sales(TTM) 1.12 | ||
Enterprise Value to Revenue 0.27 | Enterprise Value to EBITDA -1.71 | Shares Outstanding 255883008 | Shares Floating 1023293789 |
Shares Outstanding 255883008 | Shares Floating 1023293789 | ||
Percent Insiders 0.38 | Percent Institutions 60.27 |
AI Summary
Adaptimmune Therapeutics Plc: A Comprehensive Overview
Company Profile:
Detailed History and Background: Adaptimmune Therapeutics Plc (ADAP) is a clinical-stage biopharmaceutical company founded in 2008. Headquartered in Oxford, UK, the company specializes in the development of novel T-cell therapies for the treatment of cancer and other serious diseases.
Their core technology, known as SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform, allows engineers to modify T-cells to target specific tumor antigens with high affinity and kill cancer cells with precision. The company has a broad pipeline of product candidates in various stages of development, targeting a range of hematological malignancies and solid tumors.
Core Business Areas:
- Discovery and Development: Adaptimmune focuses on research and development of its SPEAR T-cell platform and its application in treating various cancers.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Manufacturing and Collaboration: Adaptimmune collaborates with partners for manufacturing and commercialization of its therapies.
Leadership Team and Corporate Structure: The company is led by CEO John Lunger, MD, PhD, and a team of experienced executives with expertise in drug development, clinical research, and business development. The corporate structure comprises various departments such as Research & Development, Clinical Development, Manufacturing, and Finance.
Top Products and Market Share:
Top Products: Adaptimmune's lead product candidate is ADP-A2M4, a T-cell therapy targeting the MAGE-A4 antigen for the treatment of synovial sarcoma and other MAGE-A4 positive cancers. Other key candidates include ADP-A2M4CD8, ADP-A2M4PSMA, and NY-ESO-1 T-cell therapy.
Market Share: The company is still in the clinical development stage and has not yet commercialized any products. Therefore, it does not have a market share in the global or US markets.
Product Performance and Market Reception: Initial data from clinical trials of ADP-A2M4 has shown promising results in terms of safety and efficacy. However, it is too early to assess the product's overall market reception as it is yet to be approved and launched commercially.
Total Addressable Market:
The global market for T-cell therapies is expected to reach USD 14.8 billion by 2027, and the US market is projected to contribute significantly to this growth. This indicates a substantial addressable market for Adaptimmune's products in the coming years.
Financial Performance:
Recent Financial Statements: As of December 31, 2022, Adaptimmune had USD 253.9 million in cash and equivalents and USD 5.5 million in revenue. The company reported a net loss of USD 147.7 million during the year. As a clinical-stage company, Adaptimmune is not yet profitable.
Year-over-Year Performance: While the company's revenue has increased compared to the previous year, it still incurs significant losses due to research and development costs associated with its pipeline.
Cash Flow and Balance Sheet: Adaptimmune has a strong cash position and expects its current cash reserves to be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months.
Dividends and Shareholder Returns:
Dividend History: Adaptimmune does not currently pay dividends to shareholders as it is focused on reinvesting its resources into R&D and growth initiatives.
Shareholder Returns: The company's stock price has been volatile in recent years, with a total return of -67.8% over the past year and -85.7% over the past five years.
Growth Trajectory:
Historical Growth: Adaptimmune has demonstrated significant growth in its pipeline development and clinical trial progress. The company has advanced several candidates into late-stage trials and expanded its collaboration network.
Future Growth Projections: The company's future growth will depend on the success of its clinical trials and regulatory approvals for its product candidates. Positive outcomes could lead to significant market entry and revenue growth.
Recent Product Launches and Initiatives: Adaptimmune continues to invest heavily in R&D and has several ongoing clinical trials for its lead product candidates. Additionally, the company is exploring strategic partnerships and collaborations to expand its reach and access to markets.
Market Dynamics:
Industry Trends: The T-cell therapy market is experiencing rapid growth driven by technological advancements and increasing adoption of personalized cancer treatments. However, the market is also highly competitive, with several established players and emerging companies vying for market share.
Adaptimmune's Positioning: Adaptimmune's SPEAR T-cell platform offers several advantages, including high specificity, potential for durable responses, and the ability to target multiple tumor antigens. The company's focus on solid tumors and unmet medical needs further positions it within a growing market segment.
Competitors:
Key Competitors: Major competitors in the T-cell therapy space include:
- Kite Pharma (KITE)
- Novartis (NVS)
- Gilead Sciences (GILD)
- Bristol Myers Squibb (BMY)
- TCR2 Therapeutics (TCRR)
Market Share Comparison: As Adaptimmune has not yet commercialized any products, it does not have a market share. However, its competitors have established market positions, with Kite Pharma leading the US market with a 30% share.
Competitive Advantages and Disadvantages: Adaptimmune's advantages include its proprietary SPEAR platform, differentiated product candidates, and focus on solid tumors. However, the company faces challenges in terms of competition from established players, limited commercial experience, and regulatory hurdles.
Potential Challenges and Opportunities:
Key Challenges: Adaptimmune faces challenges such as navigating the complex regulatory landscape, demonstrating the long-term efficacy of its therapies, and competing with established players in the market.
Potential Opportunities: Opportunities include the successful development and commercialization of its product candidates, expanding into new markets, and forging strategic partnerships to enhance its reach and capabilities.
Recent Acquisitions:
Adaptimmune has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Based on an AI-based analysis using publicly available data, Adaptimmune Therapeutics Plc is given a fundamental rating of 5 out of 10. This rating considers factors such as the company's pipeline, cash position, competitive landscape, and market opportunities.
The rating acknowledges the promising potential of the company's SPEAR T-cell platform and its pipeline of candidates targeting high-need areas. However, the challenges related to clinical development, competition, and regulatory approvals are also factored into the rating.
Sources and Disclaimers:
This overview is based on information gathered from the following sources:
- Adaptimmune Therapeutics Plc official website (https://www.adaptimmune.com/)
- SEC filings
- Market research reports
- Financial news articles
This information is intended for educational purposes only and should not be considered as financial advice. Investing in any stock involves inherent risks, and you should consult with a qualified financial professional before making any investment decisions.
About Adaptimmune Therapeutics Plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-05-06 | CEO, Principal Accounting Officer & Director Mr. Adrian G. Rawcliffe | ||
Sector Healthcare | Industry Biotechnology | Full time employees 449 | Website https://www.adaptimmune.com |
Full time employees 449 | Website https://www.adaptimmune.com |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.